To characterize the clinical and molecular phenotype of FSHD.
The purpose of this study is to validate alterations in therapeutically relevant biomarkers in muscle tissue from FSHD patients. These biomarkers are responsive to the upregulation of the DUX4 gene and protein, which is the fundamental molecular defect in FSHD. In anticipation of a future clinical trial, the Investigators intend to assess the correlation between the expression of these relevant biomarkers and clinical functional measures. The Investigators will also explore the utility of muscle MRI in identifying regions of muscle suitable for sampling for relevant biomarkers, as MRI-related signal changes have been proposed as an anatomic marker of early FSHD pathology.
Study Type
OBSERVATIONAL
Enrollment
1
The Abigail Wexner Research Institute at Nationwide Children's Hospital
Columbus, Ohio, United States
Validation of Biomarkers
To validate alterations in therapeutically relevant biomarkers in muscle tissue from FSHD participants. Each participant will provide data at a single timepoint. The data in totality will be reviewed upon study completion.
Time frame: Through study completed, anticipated to be 4 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.